mp.weixin.qq.com·· 5 hours agoPickScore63
HBM Biosciences' Batoclimab Approved in China for AChR Antibody-Positive Generalized Myasthenia Gravis
In brief
HBM Biosciences' batoclimab injection has been approved for market launch at a strength of 170 mg/1 mL, for use in combination with conventional therapy in adult patients with generalized myasthenia gravis who are positive for AChR antibodies. Professor Chongbo Zhao of the Department of Neurology at Huashan Hospital, Fudan University, said batoclimab is the first FcRn-targeted therapy to complete full clinical development in China.
Why it matters
The source states the 170 mg/1 mL strength and the combination-therapy condition for AChR antibody-positive adults with gMG, clarifying the approval's scope.
Source: mp.weixin.qq.com · mp.weixin.qq.com